In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innovation

Set Alert for Innovation

Underserved Areas: Looking Beyond Cancer And Rare Diseases

Oncology and rare diseases dominate the industry pipeline, fuelled by science, regulatory tailwinds and high prices. But as the world grapples with coronavirus, and with heart disease still the top killer, can our systems fund treatments for more prevalent conditions?

Clinical Trials Research and Development Strategies Research & Development

Latest From Innovation

COVID-19 Pandemic Accelerates Shift Toward Virtual Trials

As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation. 

Coronavirus COVID-19 Clinical Trials

mRNA Vaccines – Trials Line Up Against Coronavirus

The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.

Coronavirus COVID-19 Innovation

EU Health Innovation Partnership Reflects Medtech’s Role In Unmet Needs

The EU Partnership on Health Innovation, a new public private health care research partnership, is in the final drafting phase before its launch under Horizon Europe. In Vivo asked the partnership’s medtech industry lead, Patrick Boisseau, to set out the innovation challenges for participants as they address unmet health care needs in Europe.

Innovation Medical Device

Redbiotec Pivots Toward HSV-2 Therapies And Therapeutic Bacteria

Redbiotec has reached a new inflection point as it progresses two key programs in herpes and cancer. The company’s CEO and CSO explain how it hopes to use bacteria as a delivery system for genes or proteins to treat cancer.

Commercial Innovation

The Tumor-Agnostic Developer’s Toolkit

In Vivo has identified the pipeline of next-generation tumor-agnostic drugs and created a guide to the ideal trial strategies for these potentially transformative candidates.

Commercial Innovation

Bringing A Different Science Into Solid Tumor Treatment

Depending on the regulatory jurisdiction, Nanobiotix’s radiation-activated cancer nanotechnology may be a drug or a device. But regardless of classification, it offers a physical solution to problems that chemistry and biology cannot solve.

Innovation Cancer
See All
UsernamePublicRestriction

Register